Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2

Conditions: Multiple Indications Cancer

Treatments: Drug: Dasatinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT02297139

CA180-597

Details and patient eligibility

About

The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.

Enrollment: 17 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol
• Receiving dasatinib at the time of signature of informed consent
• Males and Females, ages 18 and older

Exclusion Criteria:

• All patients previously discontinued from a dasatinib study for any reason
• Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
• History of allergy to dasatinib

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 1 patient group

Dasatinib

Experimental group

Description:

This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol

Treatment:

Drug: Dasatinib